<font color="blue">Effect_1</font> of treatment with paromomycin on <font color="blue">endotoxemia_1</font> in patients with alcoholic liver disease -- a double - blind , placebo - controlled trial . 
<br>
<br> The results of experimental and clinical studies support the hypothesis that <font color="blue">gut_1</font> <font color="blue">-_1</font> <font color="blue">derived_1</font> <font color="blue">endotoxins_1</font> might be of relevance for the development and course of alcoholic liver disease . The aim of this study was to <font color="blue">test_1</font> <font color="blue">the_1</font> <font color="blue">effect_2</font> <font color="blue">of_1</font> <font color="blue">a_1</font> <font color="blue">nonabsorbable_1</font> <font color="blue">,_1</font> <font color="blue">broad_1</font> <font color="blue">-_1</font> <font color="blue">spectrum_1</font> <font color="blue">antibiotic_1</font> on <font color="blue">endotoxemia_1</font> in patients with alcoholic liver disease . Fifty patients with <font color="blue">alcoholic_1</font> <font color="blue">liver_1</font> <font color="blue">disease_1</font> ( 27 with cirrhosis , 23 without cirrhosis ) were randomly assigned to receive either paromomycin sulfate ( 3 x 1 g / day ) or placebo in a double - blind fashion for at least 3 weeks , and if possible 4 weeks . <font color="blue">Endotoxin_2</font> <font color="blue">concentration_2</font> <font color="blue">,_2</font> <font color="blue">liver_2</font> <font color="blue">function_2</font> <font color="blue">tests_2</font> <font color="blue">,_2</font> <font color="blue">and_2</font> <font color="blue">other_2</font> <font color="blue">laboratory_2</font> <font color="blue">parameters_2</font> were determined in weekly intervals . Endotoxin concentration was also determined in 15 healthy controls . Groups receiving paromomycin or placebo were similar for clinical and biological items collected initially . <font color="blue">Mean_4</font> <font color="blue">initial_4</font> <font color="blue">endotoxin_5</font> <font color="blue">concentrations_5</font> were <font color="blue">significantly_1</font> <font color="blue">elevated_1</font> in both groups ( mean + /- SEM ; paromomycin , 16.7 + /- 5.3 pg / ml ; placebo , 17.5 + /- 6.9 pg / ml ; healthy controls , 2.3 + /- 0.4 pg / ml ) . Although the <font color="blue">mean_2</font> <font color="blue">endotoxin_3</font> <font color="blue">concentration_3</font> <font color="blue">was_1</font> <font color="blue">lower_1</font> in the verum group after 1 week ( paromomycin , 8.0 + /- 1.9 pg / ml ; placebo , 14.6 + /- 3.5 pg / ml ; p > 0.05 ) , <font color="blue">paromomycin_1</font> <font color="blue">treatment_1</font> <font color="blue">had_1</font> <font color="blue">no_1</font> <font color="blue">significant_1</font> <font color="blue">effect_1</font> <font color="blue">on_1</font> <font color="blue">endotoxin_3</font> <font color="blue">concentration_3</font> <font color="blue">or_2</font> <font color="blue">liver_3</font> <font color="blue">function_3</font> <font color="blue">tests_3</font> during the 4-week period . The beneficial <font color="blue">effect_1</font> <font color="blue">of_1</font> <font color="blue">paromomycin_1</font> <font color="blue">treatment_1</font> <font color="blue">on_1</font> <font color="blue">endotoxemia_2</font> in cirrhotics reported in earlier studies could not be reproduced under the conditions of this trial in patients with <font color="blue">alcoholic_1</font> <font color="blue">liver_1</font> <font color="blue">disease_1</font> <font color="blue">._1</font>